Table 1. Study characteristics. (OL = Olanzapine-containing groups).

Study	Ethnicity	control	Period	OL group		control group		Characteristics
CR	all	CR	all
Mizukami N et al. 2013	Japanese	Vomiting control	Acute	22	22	19	22	Moderately or highly emetogenic chemotherapyC: corticosteroid + 5-HT3receptor antagonist + NK-1 receptor antagonistO: C regimen + O 5 mg/d days 0–4
Delayed	22	22	16	22
Overall	22	22	15	22
Navari RM et al. 2011	American	Vomiting control	Acute	97	121	87	120	Highly emetogenic chemotherapyC: corticosteroid + 5-HT3 receptor antagonist + NK-1 receptor antagonistO: C regimen + O 10 mg/d days 1–4
Delayed	77	121	73	120
Overall	77	121	73	120
Nausea control	Acute	87	121	87	120
Delayed	69	121	38	120
Overall	69	121	38	120
Tan L et al. 2009	Chinese	Vomiting control	Acute	114	121	101	108	Moderately or highly emetogenic chemotherapyC:corticosteroid + 5-HT3 receptor antagonistO: C regimen + O 10 mg/d days 1–5
Delayed	102	121	73	108
Overall	102	121	63	108
Nausea control	Acute	117	121	98	108
Delayed	93	121	50	108
Overall	93	121	48	108
WK Mao et al. 2011	Chinese	Vomiting control	Acute	45	46	38	46	Moderately or highly emetogenic chemotherapyC: corticosteroid + 5-HT3 receptor antagonistO: C regimen + O 10 mg/d days non unspecified
Delayed	39	46	23	46
Overall	38	46	15	46
X Wang et al. 2012	Chinese	Vomiting control	Acute	40	60	27	60	Highly emetogenic chemotherapyC: 5-HT3 receptor antagonistO: C regimen + O 10 mg/d days 1–8
Delayed	46	60	32	60
Nausea control	Acute	46	60	42	60
Delayed	49	60	45	60
YL Lv et al. 2013	Chinese	Vomiting control	Overall	22	30	11	30	Moderately or highly emetogenic chemotherapyC: diphenhydramine + corticosteroid + 5-HT3 receptor antagonistO: C regimen + O 5 mg/d days 1